Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02595944 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Study acronym: ANVIL
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Dec 31, 2026 → May 31, 2027
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 908 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 31, 2026 to May 31, 2027 Study sites revised (884) Show 1 more changeShow less
    • Study sites revised (884)
  2. Primary and study completion dates: Dec 31, 2026 to May 31, 2027 Site details revised at 82 of 884 sites Show 1 more changeShow less
    • Site details revised at 82 of 884 sites
  3. Re-verified, no change to tracked fieldsv906
  4. Study sites revised (884)v905 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 885 to 884v904
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (885)v903 See this version in full on ClinicalTrials.gov ↗
  2. Study sites revised (885)v902 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (885)v901 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (885)v900 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (885)v899 See this version in full on ClinicalTrials.gov ↗
  6. Re-verified, no change to tracked fieldsv898
  7. Study sites: 886 to 885v897
  8. Study sites revised (886)v896 See this version in full on ClinicalTrials.gov ↗
  9. 19 versions Re-verified since Mar 14, 2026, no change to tracked fieldsv877-v895
  10. Study Status, Contacts/Locationsv876
  11. 17 versions Re-verified since Feb 18, 2026, no change to tracked fieldsv859-v875
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Trial Details
NCT Number NCT02595944
Lead Sponsor National Cancer Institute (NCI)
Conditions Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Enrollment 903 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov